ストックスクリーナーアプリを入手
1.395
1.09%
0.015
アフターアワーズ：
1.40
0.005
+0.36%
前日終値:
$1.38
開ける：
$1.38
24時間の取引高:
22,420
Relative Volume:
0.44
時価総額：
$3.92M
収益：
-
当期純損益:
$-18.35M
株価収益率:
-1.2026
EPS:
-1.16
ネットキャッシュフロー:
$-19.20M
1週間 パフォーマンス:
-1.06%
1か月 パフォーマンス:
+29.17%
6か月 パフォーマンス:
-29.19%
1年 パフォーマンス:
-99.45%
1日の値動き範囲:
$1.3201
$1.465
1週間の範囲:
$1.29
$1.465
52週間の値動き範囲:
$0.9563
$306.94
Theriva Biologics Inc Stock (TOVX) Company Profile
名前
Theriva Biologics Inc
セクター
電話
301 417 4364
住所
9605 Medical Center Drive, Suite 270, Rockville
TOVX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
1.395 | 3.92M | 0 | -18.35M | -19.20M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Theriva Biologics Inc (TOVX) 最新ニュース
Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Up 6.8% – Should You Buy? - Defense World
Theriva Biologics Announces Presentation of Data from the - GlobeNewswire
Major Clinical Trial Update: Theriva's SYN-004 Shows Promise in Transplant PatientsKey Data Revealed - Stock Titan
Synthetic Biologics stock plunges to 52-week low at $1.02 - Investing.com Australia
Synthetic Biologics stock plunges to 52-week low at $1.02 By Investing.com - Investing.com South Africa
Theriva Biologics Completes Enrollment For VIRAGE Trial, Topline Data Expected In Q2 2025 - Nasdaq
Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Ad - GlobeNewswire
Cancer Drug Breakthrough: Independent Committee Confirms Positive Safety Data in Phase 2b Pancreatic Trial - Stock Titan
Theriva Biologics (NYSEAMERICAN:TOVX) Shares Down 1.4% – Should You Sell? - Defense World
Theriva Biologics to Present at the CAGLA NeauxCancer 2025 Conference in New Orleans - Nasdaq
Theriva™ Biologics to Present at the 2025 NeauxCancer Conference - GlobeNewswire
Theriva Biologics Reports 2024 Financial Results and Progress - TipRanks
Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results - The Manila Times
Can Theriva's PDAC Trial Success and FDA Fast Track Save Its Dwindling Cash Position? - StockTitan
Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual - The Manila Times
Cancer Therapeutics Company Theriva Sets Key Investor Presentation DateWhat to Expect - StockTitan
Theriva Biologics Inc Inc. (TOVX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
US Stocks To Open Higher On Shortened Trading Day: Santa Claus Rally Period Officially Begins, Says Analyst - Benzinga
Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket - Benzinga
Synthetic Biologics stock hits 52-week low at $1.21 - Investing.com India
Synthetic Biologics stock hits 52-week low at $1.21 By Investing.com - Investing.com UK
Theriva Biologics outlines Phase 3 study for cancer drug By Investing.com - Investing.com Canada
Theriva™ Biologics Announces U.S. FDA Guidance on Design of - GlobeNewswire
Theriva Biologics Gets FDA Guidance on VCN-01 Phase 3 Trial Design for Pancreatic Cancer Treatment - StockTitan
Synthetic Biologics stock hits 52-week low at $1.24 By Investing.com - Investing.com South Africa
Synthetic Biologics stock hits 52-week low at $1.24 - Investing.com
Maxim Group Has Lowered Expectations for Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price - Defense World
Theriva Biologics Highlights Key Achievements in Q3 2024 - TipRanks
Theriva Biologics: Q3 Earnings Snapshot - Houston Chronicle
Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results - GlobeNewswire
Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
What's Going On With Theriva Biologics Stock Friday? - MSN
Theriva Biologics Expands Stock Plans and Share Authority - TipRanks
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant - GlobeNewswire
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma - Yahoo Finance
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - The Globe and Mail
Synthetic Biologics stock plunges to 52-week low of $1.24 - Investing.com
Theriva Biologics dips 11%, prices 2.5M equity offering - MSN
Theriva Biologics Announces Pricing of $2.5 Million Public Offering - GlobeNewswire
Synthetic Biologics stock plunges to 52-week low of $2.66 - Investing.com
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer - Yahoo Finance
Theriva™ Biologics Awarded Manufacturing Funding from the - GlobeNewswire
Theriva Biologics (TOVX) Is Making Noise With a Promising Pipeline - Nasdaq
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket - Benzinga
What's Going On With Theriva Biologics Stock? - Benzinga
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Theriva Biologics Inc (TOVX) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
3.66%
大文字化:
|
ボリューム (24 時間):